BioPharmX Corporation(BPMX): For the most recent quarter end, BioPharmX Corporation reported Annual Earnings of $-0.13. Based on the filings, last years Annual Earnings was, $-0.86. For the most recent quarter end, BPMX reported a surprise Earnings per Share of 13.33% . The consensus estimate for current quarter is $-0.09 and for the current fiscal year, the estimate is $-0.54. For the Next fiscal year, the estimate is $-0.35 based on the consensus.
BioPharmX Corporation has received $-0.09 as the consensus Earnings Estimate for the Quarter ending on Jan 2017 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.12 while the top line estimate is $-0.08 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 50.88%. BioPharmX Corporation reported better than expected with a surprise EPS of 13.33% or $0.02 during its most recent quarterly earnings. The Actual EPS was $-0.13 compared to the Estimated EPS of $-0.15.
Company has reported several Insider transactions to the SEC, on Nov 29, 2016, Stephen Morlock (director) purchased 428,571 shares at 0.35 per share price.On Aug 16, 2016, Resources Inc Franklin (10% owner) purchased 484,615 shares at 0.65 per share price.
BioPharmX Corporation (NYSEMKT:BPMX) witnessed a decline in the market cap on Wednesday as its shares dropped 2.66% or 0.0123 points. After the session commenced at $0.47, the stock reached the higher end at $0.47 while it hit a low of $0.44. With the volume soaring to 651,706 shares, the last trade was called at $0.45. The company has a 52-week high of $1.59. The company has a market cap of $30 million and there are 67,719,577 shares in outstanding. The 52-week low of the share price is $0.1883.
BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for womens health, dermatology and otolaryngology markets. The Companys product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmXs breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.